Fig. 1 | Nature Communications

Fig. 1

From: Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate

Fig. 1

Longitudinal imaging in mutant IDH1 glioma patients treated with IDH305 inhibitor. a Baseline anatomical, structural and metabolic maps before treatment. b Follow-up anatomical, structural, and metabolic maps after 1 week of IDH305 treatment. Metabolic maps are converted to mM by reference to healthy creatine levels. The color bars ranges are 0–3 mM (2HG), 0–20 mM (Glx), 0–1 mM (GSH), 0–16 mM (Lac), 0–3 mM (tCho), 0–20 mM (NAA), and 0–4 μm2/ms (ADC). On the right, examples of 2HG edited spectra (black trace) and the LCModel fits (red trace) are shown

Back to article page